일본의 암 백신 시장 규모는 2024년도 10억 5,000만 달러에서 2032년도에 16억 8,000만 달러에 달할 것으로 예측되며, 2025-2032년도의 예측 기간에 CAGR로 6%의 성장이 전망됩니다. 암을 예방하고 치료할 필요성이 증가함에 따라 시장이 빠르게 확대되고 있습니다. 백신은 암으로 인한 이환율과 사망률을 낮추기 위해 필수적입니다. 시장 성장은 암 환자 증가, 정부의 강력한 예방접종 프로그램, 대중의 인식 개선, mRNA 백신 및 유전자 재조합 백신과 같은 백신 기술의 발전으로 인해 개발 및 생산이 가속화되고 있습니다. 제약기업과 생명공학 기업의 연구개발 투자 증가는 HIV, 암과 같은 질병에 대한 혁신적인 백신의 개발로 이어지고 있습니다. 또한 특히 개발도상국에서는 정부 기관이 적극적으로 자금을 지원하고 대규모 백신 접종 캠페인을 지원하고 있습니다. 생명공학 대기업은 큰 성과를 낼 수 있도록 힘을 모으고 있습니다. 예를 들어 아스텔라스제약(Astellas Pharma Inc.)은 항-CLDN18.2 모노클로널 항체 Vyloy(졸베툭시맙)가 일본 후생노동성으로부터 CLDN18.2 양성 절제 불가능한 진행성 및 재발성 위암 환자의 치료제로 승인받았다고 발표했습니다. CLDN18.2를 표적으로 하는 치료제로는 세계 최초이자 유일하게 규제 당국의 승인을 받았습니다. 유리한 규제 정책과 의료비 증가는 시장 확대를 더욱 촉진할 것입니다. 고령 인구 증가, 신흥 경제국의 의료 인프라 개발, 세계 백신 접종률의 확대는 시장의 장기적인 성장을 유지할 것으로 예상됩니다.
일본의 암 백신 시장에 대해 조사분석했으며, 시장 규모와 예측, 시장 역학, 주요 기업의 상황 등을 제공하고 있습니다.
Japan cancer vaccines market is projected to witness a CAGR of 6% during the forecast period FY2025-FY2032, growing from USD 1.05 billion in FY2024 to USD 1.68 billion in FY2032. Japan cancer vaccines market is expanding rapidly, driven by the increasing need to prevent cancer, and cure it. Vaccines are essential for reducing morbidity and mortality from cancer. The market's growth is fueled by rising cases of cancer, strong government immunization programs, and increasing public awareness. Advancements in vaccine technology, such as mRNA and recombinant vaccines, are accelerating development and production. Increased R&D investments from pharmaceutical companies and biotech firms are leading to innovative vaccines for diseases such as HIV and cancer. Additionally, government organizations are actively funding and supporting large-scale vaccination campaigns, especially in developing countries. Biotechnology giants are coming together to be able to produce big results. For example, Astellas Pharma Inc., announced that Japan's Ministry of Health, Labor and Welfare (MHLW) approved Vyloy (zolbetuximab), an anti-CLDN18.2 monoclonal antibody to treat patients with CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer. Vyloy is the first and only CLDN18.2-targeted therapy approved by any regulatory agency worldwide. Favorable regulatory policies and growing healthcare expenditures further support market expansion. The increasing geriatric population, rising healthcare infrastructure in emerging economies, and expanding global vaccination coverage are expected to sustain the market's long-term growth.
Research Breakthroughs Boosting Market Growth
One of the key factors propelling the Japan cancer vaccines market is research advancements. Innovative cancer vaccine research has been made possible by ongoing developments in immunotherapy, personalized medicine, and biotechnology. Japan has a solid background in medical research, with esteemed organizations and colleges focusing on the development of cancer vaccines. Novel antigens discovered as a result of advances in cancer immunology have made it possible to create vaccinations that specifically target and kill cancer cells. The development of innovative technologies has transformed the prevention and treatment of cancer, including mRNA and gene-based vaccinations. It is anticipated that these developments will treat different kinds of cancer, propelling market expansion. With Japan's focus on precision medicine and immuno-oncology, the country continues to make progress in understanding the molecular mechanisms of cancer, which is crucial for creating effective vaccines and therapies. For instance, NEC Bio B.V. presented interim results from a Phase 1 clinical trial of NECVAX-NEO1, an AI-driven personalized oral cancer vaccine in December 2024. The trial demonstrated the vaccine's safety and immunogenicity in patients with solid tumors, marking a significant advancement in personalized cancer immunotherapy.
Government Initiatives Fueling the Market Growth
In Japan, government measures have been instrumental in the expansion of the market for cancer vaccines. The Japanese government has continuously backed cancer research, contributing money to the creation of novel cancer treatments and vaccinations. The Ministry of Health, Labour, and Welfare (MHLW) in Japan has put more emphasis on cancer prevention in recent years, implementing public health initiatives and regulations to encourage early detection and immunization. In keeping with its goal of lowering cancer rates through immunization, the government has also started endorsing the HPV vaccine for the prevention of cervical cancer. A favorable environment for the development of cancer vaccines has also been created by Japan's significant investments in biotechnology and healthcare infrastructure. The government's commitment to reducing the cancer burden through innovation and healthcare reform is expected to drive the market's growth and accelerate the approval of new cancer vaccines. In September 2024, Japan, alongside the United States, Australia, and India, launched the Quad Cancer Moonshot Initiative. This collaborative effort seeks to reduce the cancer burden in the Indo-Pacific region by enhancing health infrastructure, expanding research, and improving access to cancer care.
Collaborative Environment Fueling the Market Growth
The market for cancer vaccines in Japan is expanding at a rapid pace due to growing alliances and partnerships between government agencies, academic institutions, and pharmaceutical businesses. The development of cancer vaccines is progressing more quickly due to partnerships between international and local actors that promote the sharing of resources, technology, and expertise. Japanese pharmaceutical giants like Takeda Pharmaceutical and Daiichi Sankyo are collaborating with foreign biotech companies and academic institutions to create innovative cancer vaccines. These collaborations lower the financial risk involved in developing a cancer vaccine while simultaneously enhancing access to cutting-edge technologies. Collaboration in clinical studies, regulatory approvals, and manufacturing procedures also guarantees that vaccines can be created effectively and get to market more quickly. The trend of collaboration enhances research, optimizes clinical testing, and brings diverse perspectives to the table, fueling innovation in cancer vaccines.
For instance, the Kawasaki Innovation Center for NanoMedicine (iCONM; Director: Kazunori Kataoka; Location: Kawasaki, Japan) have announced in collaboration with Tokyo Medical and Dental University, and Kyorin University that a group led by Prof. Satoshi Uchida, Principal Research Scientist of iCONM, has created a novel mRNA derivative and shown its high cellular immunity inducing anti-cancer activities in mice model. In tests employing melanoma and lymphoma model mice, this new mRNA exhibits strong anti-tumor effects, stimulates immune cells, and has double-stranded RNA in the form of comb teeth.
Future Market Scenario (FY2025 - FY2032F)
One of the main factors contributing to the anticipated growth of the cancer vaccines market is the increasing demand for treatment options to ensure patient safety by delivering the right quality of drug or any other such chemical product. The rising population and cases of cancer are also factors that will always propel the market's growth in the future. Given that technology is advancing, we can expect cutting-edge technology in the area. Players in this market are expanding at an unparalleled rate, introducing cost-effective and efficient technologies.
Key Players Landscape and Outlook
The key players in the market are significantly investing in the development of cancer vaccines and are utilizing strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing large-cap industry players to increase their presence and, therefore, find new opportunities in this market.
For instance, the Japan Patent Office has sent Cleveland Clinic, a partner of Anixa Biosciences, Inc., a "Decision to Grant" notice for the patent application "Vaccine Adjuvants and Formulations." This new Japanese patent extends the claims for this novel breast cancer vaccine technology to an additional geographic region, beyond the U.S. and European patents previously awarded, as explained by Dr. Amit Kumar, Chairman and CEO of Anixa, in a July 17, 2024, press release.
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.